Used in the imaging and targeted therapy of clear cell renal cell carcinoma (ccRCC), this antibody binds specifically to carbonic anhydrase 9 (CA9), a protein highly overexpressed in ccRCC but minimal in normal tissues. It enables tumor detection through radiolabeled imaging agents, aiding in diagnosis and staging. In therapeutic settings, it serves as a vehicle for delivering cytotoxic agents or radiation directly to tumor cells, minimizing damage to healthy tissue. Clinical trials have explored its role in improving specificity and outcomes in kidney cancer treatment.